RTFCCR at the Better Medicines for Children Conference 2026: Advancing Patient-Centred Pediatric Research
October 22, 2026
The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) was pleased to participate in the EFGCP Better Medicines for Children Conference 2026, held in Amsterdam on September 29–30. Bringing together stakeholders and experts from across the global pediatric development community, the conference focused this year on “Collaborating to Implement Innovative Approaches in Pediatric Development.”
The two-day program explored some of the most important developments shaping pediatric medicine today, from the evolving ethical and regulatory landscape and innovative approaches to clinical research to rare diseases, cell and gene therapies, global regulatory alignment and access to new medicines. A common thread throughout the meeting was the importance of collaboration across countries, disciplines, and stakeholder groups to accelerate the development of better treatments for children.
Paola Atzei, Senior Scientific Program Manager at RTFCCR, participated in the panel discussion “Market Access / HTA – Experience with Joint Clinical Assessment of Pediatric Medicines.” The session brought together perspectives from patient representation, regulatory and health technology assessment, industry, policy and research to discuss how new approaches to assessing medicines can support access to innovative therapies for children.
The discussion also reinforced the importance of ensuring that patients and families have a meaningful voice throughout the development and assessment of new medicines. Their involvement should go beyond participation in clinical research. Patient perspectives can help identify what outcomes matter most, highlight the real-world challenges children and families face, and ensure research and treatment development remain connected to patients’ needs.
Access to innovative therapies remains a major challenge, particularly in pediatric oncology. Limited treatment options and opportunities to participate in clinical research can all influence whether children and their families are able to benefit from scientific advances. Addressing these challenges requires collaboration across the entire ecosystem, from researchers and clinicians to regulators, industry, funders, patient advocates and families.
By listening to children and their families, understanding their experiences and priorities, and engaging them as meaningful partners in research and medicine development, we can help shape clinical trials, treatments and healthcare solutions that are more relevant, equitable and impactful.
For RTFCCR, these conversations align closely with our commitment to advancing patient-centered clinical cancer research and ensuring that patient perspectives contribute meaningfully to research and innovation that ultimately aim to improve outcomes.